Dr. Erica Sutton was a CBSSM Postdoctoral Research Fellow, 2013-2015. She is an interdisciplinary social scientist engaged in social and behavioral science research that explores the health care experiences of individuals living with rare genetic conditions; the manner in which biotechnologies shape personal experience and social life; and the ethical implications of these technologies for individuals, public health, social policy, health care institutions, and communities.
Page not found
Tanner Caverly and Jeremy Sussman were featured in the New York Times article Some Older Patients Are Treated Not Wisely, but Too Much which discusses the dangers of overtreatment and doing more harm than good.
Stephanie Kukora won a Faculty Award for Clinical Investigation/Health Services Research at the 26th Annual Pediatric Research Symposium for her work on prenatal counseling: Prognostic Failure and Decisional Mismatch in Antenatal Neonatology Consultation.
The Center for Bioethics and Social Sciences in Medicine (CBSSM) Research Colloquium was held Tuesday, April 25, 2017 at the Great Lakes Room, Palmer Commons, 100 Washtenaw Ave, Ann Arbor, MI 48109.
The CBSSM Research Colloquium featured the Bishop Lecture in Bioethics as the keynote address. Norman Daniels, PhD presented the Bishop Lecture with a talk entitled: “Universal Access vs Universal Coverage: Two models of what we should aim for."
Norman Daniels, PhD is Mary B. Saltonstall Professor of Population Ethics and Professor of Ethics and Population Health in the Department of Global Health and Population at the Harvard School of Public Health. Formerly chair of the Philosophy Department at Tufts University, his most recent books include Just Health: Meeting Health Needs Fairly (Cambridge, 2008); Setting Limits Fairly: Learning to Share Resources for Health, 2nd edition, (Oxford, 2008); From Chance to Choice: Genetics and Justice (2000); Is Inequality Bad for Our Health? (2000); and Identified versus Statistical Lives (Oxford 2015). He has published 200 peer-reviewed articles and as many book chapters, editorials, and book reviews. His research is on justice and health policy, including priority setting in health systems, fairness and health systems reform, health inequalities, and intergenerational justice. A member of the IOM, a Fellow of the Hastings Center, and formerly on the ethics advisory boards of the CDC and the CIHR, he directs the Ethics concentration of the Health Policy PhD at Harvard and recently won the Everett Mendelsohn Award for mentoring graduate students.
2017 Colloquium Schedule:
- 8:30 Check in, refreshments
- 9:05 Welcome
- 9:10 Presentation 1: “Setting priorities for Medicaid: The views of minority and underserved communities” Susan Goold, MD, MHSA, MA & Zachary Rowe, Executive Director, Friends of Parkside
- 9:35 Presentation 2: ““How Acceptable Is Paternalism? A Survey-Based Study of Clinician and Non-clinician Opinions on Decision Making After Life Threatening Stroke” Kunal Bailoor, MD Candidate
- 10:00 Medical Student in Ethics Award
- 10:10 Presentation 3: “Ethical Challenges Faced by Providers in Pediatric Death: A Qualitative Thematic Analysis” Stephanie Kukora, MD
- 10:35 Presentation 4: “Capacity for Preferences: An overlooked criterion for resolving ethical dilemmas with incapacitated patients” Jason Wasserman, PhD & Mark Navin, PhD
- 11:00 Break
- 11:15 Bishop Lecture: Norman Daniels, PhD
- 12:45 Lunch
Funded by National Institutes of Health; National Insitute on Drug Abuse
Funding Years: 2012-2017
This application seeks a five-year continuation of the panel data collections of the Monitoring the Future (MTF) study, an ongoing epidemiological and etiological research and reporting project begun in 1975. In addition to being a basic research study, MTF has become one of the nation's most relied upon sources of information on trends in illicit drug, alcohol, and tobacco use among American adolescents, college students, and young and middle-aged adults. This application seeks continuation of the mail follow-up surveys of high school graduates (augmented with internet options) at modal ages 19-30, 35, 40, 45, 50, and now 55. The companion main application seeks to continue the in-school data collections and to support the analysis of all of the data in the study, including past and future panel data. (NIDA requests that the study seek continuation funding through two separate applications, as it has done in the last two rounds.)
The study's cohort-sequential longitudinal design permits the measurement and differentiation of three types of change: age (developmental), period (historical), and cohort. Each has different determinants, and all three types of change have been shown by MTF to occur for most drugs. Factors that may explain historical trends and cohort differences also are monitored. MTF is designed to document the developmental history and consequences of drug use and related attitudes from adolescence through middle adulthood, and to determine the individual and contextual characteristics and social role transitions that affect use and related attitudes. Research on risk and protective behaviors for the transmission of HIV/AIDS among adults ages 21-40 also will be continued. All of this work will be extended to new years, cohorts, and ages under this application and the companion main application. The study will examine the importance of many hypothesized determinants of drug use (including attitudes and beliefs and access), as well as a range of potential consequences (including physical and psychological health, status attainment, role performance, and drug abuse and dependence). Impacts of some policy changes on adolescents and young adults will be evaluated, including those of the new FDA cigarette labeling requirements. MTF will experiment with the use of internet response methods and pursue several new approaches to making its panel data more accessible to other investigators.
The study's very broad measurement covers (a) initiation, use, and cessation for over 50 categories and sub-categories of licit and illicit drugs, including alcohol and tobacco; (b) attitudes and beliefs about many of them, perceived availability, and peer norms; (c) other behaviors and individual characteristics; (d) aspects of key social environments (home, work, school) and social role statuses and transitions; and (e) risk and protective behaviors related to the spread of HIV/AIDS. Results will continue to elucidate drug use from adolescence through middle adulthood (including the introduction of new drugs) with major implications for the policy, research, prevention, and treatment agendas.
PI(s): Mick Couper
Co-I(s): Lloyd Johnston, Patrick O'Malley, John Schulenberg, Megan Patrick, Richard Miech
Dr. Scherer was a VA and CBSSM Postdoctoral Research Fellow, 2010-2012. She received her PhD in social psychology in 2010 from Washington University in St. Louis.
Dr. Scherer is currently an Assistant Professor of Psychological Sciences at the University of Missouri.
Masahito Jimbo is Professor of Family Medicine and Urology at the University of Michigan. Having worked as a family physician in both urban (Philadelphia) and rural (North Carolina) underserved areas, he has first-hand knowledge and experience of the challenges faced by clinicians and healthcare institutions to be successful in providing patient care that is personal, comprehensive, efficient and timely. Initially trained in basic laboratory research, having obtained his MD and PhD degrees at Keio University in Tokyo, Japan, Dr.
Funded by the National Institutes of Health
Funding Years: 2015-2016
POINT is a randomized, double-blind, multicenter clinical trial to determine whether clopidogrel 75mg/day (after a loading dose of 600mg) is effective in improving survival free from major ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when initiated within 12 hours time last known free of new ischemic symptoms of TIA or minor ischemic stroke in subjects receiving aspirin 50-325mg/day.
PI(s): Claiborne Johnston
Co-I(s): J. Donald Easton, Mary Farrant, William Barsan, Holly Battenhouse, Robin Conwit, Catherine Dillon, Jordan Elm, Anne Lindblad, Lewis Morgenstern, Sharon Poisson, Yuko Palesch
Wendy R. Uhlmann, MS, CGC is the genetic counselor/clinic coordinator of the Medical Genetics Clinic at the University of Michigan. She is a Clinical Associate Professor in the Departments of Internal Medicine and Human Genetics and an executive faculty member of the genetic counseling training program. Wendy Uhlmann is a Past President of the National Society of Genetic Counselors and previously served on the Board of Directors of the Genetic Alliance and as NSGC’s liaison to the National Advisory Council for Human Genome Research.